BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 17636329)

  • 1. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
    Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-fluorouracil cardiotoxicity is a rare, dose and schedule-dependent adverse event: a prospective study.
    Tsavaris N; Kosmas C; Vadiaka M; Skopelitis E; Kopteridis P; Pamouki S; Efremidis M; Kasparian H; Moisakis I; Sakelariou D; Koufos C
    J BUON; 2005; 10(2):205-11. PubMed ID: 17343330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
    Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G
    Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
    J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiotoxicity induced by 5-fluorouracil or capecitabine].
    Jensen SA; Baeksgaard L; Petersen LN; Reiter L; Sørensen JB
    Ugeskr Laeger; 2010 Jan; 172(1):48-51. PubMed ID: 20056096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity.
    Shaib W; Lee V; Saif MW
    In Vivo; 2009; 23(5):821-6. PubMed ID: 19779118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine cardiotoxicity--case reports and literature review.
    Manojlovic N; Babic D; Stojanovic S; Filipovic I; Radoje D
    Hepatogastroenterology; 2008; 55(85):1249-56. PubMed ID: 18795667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
    Deboever G; Hiltrop N; Cool M; Lambrecht G
    Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
    Twelves C; Gollins S; Grieve R; Samuel L
    Ann Oncol; 2006 Feb; 17(2):239-45. PubMed ID: 16344278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
    Saif MW; Garcon MC; Rodriguez G; Rodriguez T
    In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Hoff PM; Ansari R; Batist G; Cox J; Kocha W; Kuperminc M; Maroun J; Walde D; Weaver C; Harrison E; Burger HU; Osterwalder B; Wong AO; Wong R
    J Clin Oncol; 2001 Apr; 19(8):2282-92. PubMed ID: 11304782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment.
    Molteni LP; Rampinelli I; Cergnul M; Scaglietti U; Paino AM; Noonan DM; Bucci EO; Gottardi O; Albini A
    Breast J; 2010; 16 Suppl 1():S45-8. PubMed ID: 21050310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoropyrimidine-associated cardiotoxicity: revisited.
    Saif MW; Shah MM; Shah AR
    Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
    Oshaughnessy JA; Blum J; Moiseyenko V; Jones SE; Miles D; Bell D; Rosso R; Mauriac L; Osterwalder B; Burger HU; Laws S
    Ann Oncol; 2001 Sep; 12(9):1247-54. PubMed ID: 11697835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports.
    Brickell K; Porter D; Thompson P
    Br J Cancer; 2003 Aug; 89(4):615-6. PubMed ID: 12915866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
    Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
    Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.
    de Forni M; Malet-Martino MC; Jaillais P; Shubinski RE; Bachaud JM; Lemaire L; Canal P; Chevreau C; Carrié D; Soulié P
    J Clin Oncol; 1992 Nov; 10(11):1795-801. PubMed ID: 1403060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute cardiotoxicity during capecitabine treatment: a case report.
    Bertolini A; Flumanò M; Fusco O; Muffatti A; Scarinci A; Pontiggia G; Scopelliti M
    Tumori; 2001; 87(3):200-6. PubMed ID: 11504378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine cardiac toxicity presenting as effort angina: a case report.
    Lestuzzi C; Crivellari D; Rigo F; Viel E; Meneguzzo N
    J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):700-3. PubMed ID: 20093950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.